Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual versus triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndrome
NL-OMON49131Phase 4Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Planned start Feb 2020; status: withdrawn.
02
Drugs
aspirin
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON49131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49131.